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Abstract
Background: To systematically review the benefits of cardiac resynchronization therapy
(CRT) in heart failure patients with narrow QRS (< 120 ms) who have baseline mechanical
asynchrony.
Methods: We searched the MEDLINE, Cochrane Central Register of Controlled Trials, and
reference lists of retrieved articles for relevant trials through October 2007. Studies were
included if they were clinical trials in heart failure patients with narrow QRS complex, had at
least 3 months of duration and measured baseline mechanical dyssynchrony. Weighted mean
difference (WMD) for changes in left ventricular ejection fraction (LVEF), New York Heart
Association (NYHA) class and 6 minute walk distance (6MWD) at the end of follow up period
were estimated using fixed effects meta-analysis.
Results: Three relevant clinical trials (enrolling 98 patients) out of 80 identified studies were
included in the final analysis. When compared to baseline, CRT in heart failure patients with
narrow QRS complex significantly improved mean LVEF (WMD 7.98%, 95% CI 5.94, 10.03)
and 6MWD (WMD 67 m, 95% CI 39.12, 94.98) at the end of follow up period with no significant
heterogeneity between the included studies (I2 < 50%). Similarly, there was a significant reduc-
tion in NYHA at the end of follow-up (WMD –0.87, 95% CI –1.01, –0.74) but there was
significant heterogeneity between the included studies.
Conclusions: In patients with narrow QRS complex and baseline mechanical asynchrony,
who underwent CRT after optimal medical management, there was a significant reduction in
NYHA class, improvement in LVEF and increase in 6MWD during follow up. Further data
from large randomized trials are warranted to explore the role of CRT in heart failure patients
with narrow QRS complex. (Cardiol J 2008; 15: 230–236)
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Introduction
About 5 million people in United States curren-
tly have heart failure [1, 2]. Each year about 550,000
patients are newly diagnosed with heart failure and
about 287,000 deaths occur each year which are
attributable to heart failure [1, 2]. Hospitalizations
due to heart failure are increasing [1, 3, 4] and this
is especially true with the aging population [3, 5].
In 2006, the estimated direct cost for heart failure
in United States was $ 29.6 billion dollars [1, 2].
In patients with wide QRS (> 120 ms), cardiac
resynchronization therapy (CRT) has been shown
to facilitate reverse modeling of the left ventricle
leading to increased left ventricular ejection frac-
tion, reduced mitral regurgitation and reduced he-
art size [6]. Several trials have shown that CRT in
patients with wide QRS improved quality of life,
improved exercise tolerance, and 6 min walking
distance [7–12]. More importantly, clinical trials [13, 14]
and meta-analyses [15–18] have shown that CRT
decreases mortality in heart failure patients with
wide QRS complex.
However non-response rate to CRT in heart
failure patients with wide QRS complex is repor-
ted up to 30% [19]. Baseline QRS duration has been
found to be a poor predictor of clinical and echocar-
diographic responses to CRT [20]. Clinically it is
often difficult to predict who will respond to the
CRT. Therefore, there is a need to explore other
possible factors that might play a role to get better
response to CRT. Left ventricular mechanical asyn-
chrony is one such factor which has been recently
shown to predict prognosis in patients with CRT
[21–23]. Recent studies have also shown that there is
a high prevalence of left ventricular mechanical asyn-
chrony in patients with narrow QRS (< 120 ms) [24].
Only few clinical trials have looked at the benefit of
CRT in patients with narrow QRS [25–31]. Since
there is a high prevalence of left ventricular asyn-
chrony in heart failure patients with narrow QRS
complexes, and there is a need to explore the role
of CRT in these group of patients, we aimed to sys-
tematically review the benefits of CRT in heart fa-
ilure patients with narrow QRS who have baseline
mechanical asynchrony.
Methods
Search strategy
We searched MEDLINE and the Cochrane Con-
trolled Trials Register in October 2007 for clinical
trials of CRT in heart failure patients with narrow
QRS complex using the appropriate terms: cardiac
resynchronization therapy, heart failure, congesti-
ve heart failure, pacemaker, narrow QRS complex.
Study selection/data extraction
Two investigators independently screened all
titles and abstracts to identify the studies which
looked at benefits of CRT in patients with narrow
QRS complex and heart failure. One of these revie-
wers extracted relevant data using a standardized
data extraction from the included studies. Disagre-
ements were resolved by discussion with James P.
Daubert. Both randomized and non-randomized stu-
dies with a follow-up period of at least 3 months
were considered for inclusion. Changes in left ven-
tricular ejection fraction (LVEF), NYHA class and
6 minute walk distance (6MWD) at the end of fol-
low up period were the primary outcome measu-
res. Studies were excluded if the effects of CRT
were not reported separately from CRT with im-
plantable cardioverter defibrillator (ICD).
Statistical analysis
Statistical analyses were performed using the
Cochrane Revman software 4.2.8 and the results were
expressed as weighted mean difference (WMD) for
continuous outcomes, with 95% confidence intervals
(95% CI) using fixed effects model. We planned to
conduct sensitivity analyses if significant heteroge-
neity was found (I2) for any one of the outcomes.
Results
Search results
Three relevant clinical trials (enrolling 98 pa-
tients) out of 80 studies were included in the final
analysis (Fig. 1). The trials included in this meta-
analysis for narrow QRS studies were reported by
Yu et al. [25], Bleeker et al. [26] and Achilli et al. [28],
two trials Turner et al. [29] and Gasparini et al. [31]
were excluded as these studies did not measure ba-
seline LV dyssynchrony. The baseline characteri-
stics of the studies included in meta-analysis for nar-
row QRS are shown in Table 1 and 2. Primary out-
comes of the studies included are shown in Table 3.
Left ventricular ejection fraction
When compared to baseline, CRT in patients
with narrow QRS complex improved mean LVEF
(3 studies, 98 patients, WMD 7.98%, 95% CI 5.94,
10.03) without any significant heterogeneity be-
tween the included studies (c2 = 0.41, p = 0.82,
I2 = 0%) (Fig. 2).
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heterogeneity between the included studies (c2 =
= 2.8, p = 0.24, I2 = 30.3%) (Fig. 3).
Change in NYHA classification
There was a significant reduction in NYHA at
the end of follow-up period with CRT in patients
with narrow QRS complex (3 studies, 98 patients,
WMD –0.87, 95% CI –1.01, –0.74) with significant
heterogeneity between the included studies (c2 =
= 15.18, p = 0.0005, I2 = 86.8%) (Fig. 4).
Sensitivity analysis
Heterogeneity was explored through sensitivi-
ty analyses and the exclusion of the trial by Achili
et al. [28] eliminated the heterogeneity for change
in NYHA. This is probably related to the smaller
sample size in this study compared to the other two
studies included in the analyses.
Discussion
Our meta-analysis showed that there was a signi-
ficant improvement in mean LVEF and 6MWD at the
end of follow up period. Similarly, there was a signifi-
cant reduction in NYHA at the end of follow-up period.
These results suggest that there is a potential role of
CRT in narrow QRS complex heart failure patients.
Figure 1. Study Selection from MEDLINE search.
Six minute walk distance (6MWD)
In comparison to baseline, CRT in patients with
narrow QRS complex increased the 6MWD signifi-
cantly (3 studies, 98 patients, WMD 67 m, 95% CI
39.12, 94.98) at the end of follow up period with no
Table 1. Baseline characteristics of studies included in the meta-analysis.
Study Objective Study Outcomes analyzed Findings
duration
(months)/
/No. of
patients
Bleeker Role of CRT in HF 6/33 1. Reduction in NYHA class Significant improvement
et al. [26] patients with narrow 2. Improvement in 6MWD of NYHA functional class,
QRS (<120 ms) and 3. Improvement in LVEF (%) improvement in 6MWD,
echocardiographic 4. Improvement in QoL improvement in LVESV
evidence of baseline 5. Reduction in LVESV
asychrony 6. Reduction in LVEDV
Yu Effects of CRT in HF 3/51 1. Reduction in NYHA class Significant improvement
et al. [25] patients with narrow 2. Improvement in 6MWD of NYHA functional class,
QRS (< 120 ms) and 3. Improvement in LVEF (%) improvement in 6MWD,
evidence of baseline 4. Improvement in QoL improvement in LVESD,
asynchrony on tissue 5. Reduction in LVESD Reduction in mitral
Doppler imaging 6. Reduction in LVEDD regurgitation area
Achilli Effects of CRT in 6/14 1. Reduction in NYHA class Significant improvement
et al. [28] refractory HF patients 2. Improvement in 6MWD of NYHA functional class,
with narrow QRS 3. Improvement in LVEF (%) improvement in 6MWD,
(< 120 ms) and 4. Reduction in LVESD improvement in LVESD,
evidence of baseline 5. Reduction in LVEDD reduction in mitral
asynchrony on regurgitation area
echocardiography
CRT — cardiac resynchronization therapy; HF — heart failure; NYHA — New York Heart Association heart failure class; QoL — quality of life;
6MWD — 6 min walk distance; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVEDD — left ventricular
end-diastolic diameter; LVESV — left ventricular end-systolic volume; LVESD — left ventricular end-systolic diameter
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Table 2. Characteristics of trials included in meta-analysis.
Baseline characteristics Bleeker et al. [26] Yu et al. [25] Achilli et al. [28]
Mean QRS 110±8 103±13 NA
Age (mean ± SD) 63±11 63±11 68.3±8
Men 85% 78.4% 71%
Ischemic 70% 49% 29%
NYHA 3.1±0.3 2.84±0.46 3.4±0.5
QoL 39±18 28±14 NA
6MWD [m] 274±133 333±96 276.4±88.9
LVEF (%) 22±6 27.8±7 24.6±5.0
LVEDV1 [cc]/LVEDD2 [mm] 216±781 167±471 71.8±9.22
LVESV1 [cc]/LVESD2 [mm] 174±751 122±421 61.4±8.42
Left ventricular dyssynchrony 102±32 35.9±14.0 NA
Diuretics 82% 96% 100%
ACEI 88% 92% 90%*
Beta-blocker 76% 67% 60%
NA — not available; NYHA — New York Heart Association heart failure class; QoL — quality of life; 6MWD — 6 min walk distance; LVEF — left ventricular
ejection fraction; LVEDV — left ventricular end-diastolic volume; LVEDD — left ventricular end-diastolic diameter; LVESV — left ventricular end-systolic
volume; LVESD — left ventricular end-systolic diameter;  ACEI — angiotensin converting enzyme inhibitor; *including angiotensin receptor blockers
Table 3. Primary outcomes after cardiac resynchronization therapy at 6 months.
Bleeker et al. [26] Yu et al. [25] Achilli et al. [28]
Reduction in NYHA 0.9 ± 0.6 0.73 ± 0.4 1.6 ± 0.1
Reduction in QoL 13 ± 16 8 ± 19 NA
Improvement 6MWD 89 ± 107 46 ± 88 93.5 ± 18.7
Improvement in LVEF (%) 8 ± 8 7.3 ± 6.3 9 ± 0.9
Reduction in LVEDV1 [cc]/LVEDD2 [mm] 26 ± 321 8.6 ± 141 6.2 ± 0.72
Reduction in LVESV1 [cc]/LVESD2 [mm] 39 ± 341 17.1 ± 18.61 5.8 ± 0.22
All cause mortality 9 NA 3/14
Sudden death 0 NA 1
Progressive heart failure deaths 8 NA 2
Noncardiac deaths NA NA 0
Hospitalizations 6 NA NA
NA — not available; NYHA — New York Heart Association heart failure class; QoL — quality of life; 6MWD — 6 min walk distance; LVEF — left ventricular
ejection fraction; LVEDV — left ventricular end-diastolic volume; LVEDD — left ventricular end-diastolic diameter; LVESV — left ventricular end-systolic
volume; LVESD — left ventricular end-systolic diameter
Although the role of CRT in heart failure pa-
tients with wide QRS (> 120 ms) is established,
about 30 to 40% of patients do not respond to tre-
atment [19]. The usefulness of QRS duration as
a selection criterion among these patients has
been questioned. There is a need to identify other
factors that might help improve outcomes among
patients with CRT. Left ventricular asynchrony
is an important factor which predicts prognosis
in patients with CRT [21–23]. Some of the other
reported predictors of non-response to CRT include
ischemic heart disease, severe MR and LVEDD ≥
≥ 75 mm [32]. Incidence of left ventricular
dyssynchrony in heart failure patients vary betwe-
en 27% to 56% and one study which specifically
looked at narrow QRS complex heart failure pa-
tients reported 33% of left ventricular dyssyn-
chrony [33].
Only few studies have looked at the potential
role of CRT in patients with narrow QRS [25–31].
CRT has been shown to improve hemodynamics in
CHF patients with narrow QRS [34]. Similarly, our
systematic review shows significant improvement
in clinical and functional parameters in narrow QRS
complex patients who had CRT when compared to
their baseline.
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Figure 2. Improvement in left ventricular ejection fraction in heart failure patients with narrow QRS and baseline
asynchrony at follow up compared to baseline.
Figure 4. Improvement in New York Heart Association class in heart failure patients with narrow QRS and baseline
asynchrony at follow up compared to baseline.
Figure 3. Improvement in 6 minute walk distance in heart failure patients with narrow QRS and baseline asynchrony
at follow up compared to baseline.
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Gasparini et al. [31] studied the long term ef-
fects of CRT in heart failure patients with QRS £
£ 120 ms. Patients in this study were not pre-se-
lected by echocardiographic presence of dyssyn-
chrony. When we included the data at 6 months fol-
low up from Gasparini et al. [31] to other three trials,
6MWD increased significantly (4 studies, 143 pa-
tients, WMD 63 m, 95% CI 38.85, 87.12) at the end
of follow up period with no heterogeneity. Similar-
ly LVEF increased (4 studies, 143 patients, WMD
7.73%, 95% CI 6.00, 9.47) without any significant
heterogeneity. Further Gasparini et al. [31] had fol-
low up for 36 months. When we included data at
36 months follow up there was a greater increase
in 6MWD and LVEF. This shows that we need more
data from long term trials which would allow ade-
quate time for left ventricular remodeling.
Limitations of the study
One of the major limitations of the study is that
the included studies are pre and post CRT studies
without any randomization and any control group.
So there is a potential risk of bias. Further we were
unable to analyze the potential mortality benefit of
CRT in narrow QRS complex patients because the
available trials did not have a control arm with opti-
mal medical management. Thus, the results will
need to be interpreted with caution.
Recently study by Beshai et al. [35] showed
that CRT in heart failure patients with narrow QRS
complex did not improve peak oxygen consumption,
Minnesota living with heart failure scores, 6 min
walk distance and left ventricular volume and ejec-
tion fraction at 6 months. Potential differences in
these results could be due to the method of measu-
rement of mechanical dyssynchrony and lack of do-
cumentation. Beshai et al. [35] used opposite wall
delay method to measure mechanical dyssynchrony
whereas asynchrony index was used by Yu et al. [25],
maximum delay between peak systolic velocities
among the 4 walls within the left ventricle using
tissue Doppler imaging was used by Bleekar et al. [26]
and intraventricular asynchrony was identified
when Q-LW > Q-E and Q-LW > 9.9 corrected units
(c.u. = measured interval in ms/÷ R-R interval) by
Achilli et al. [28].
Further from Gasparini’s trial we know that the
benefits are significantly higher with longer dura-
tion. Perhaps we need data from trials with longer
duration. Another protocol for a randomized clini-
cal trial in heart failure patients with narrow QRS
complex patients has been released from Universi-
ty of Zurich [36]. The results of this trial along with
results from ReThinQ [35] after a longer duration
of follow up would help us understand the role of
CRT in narrow QRS heart failure patients.
Conclusions
In summary, CRT in heart failure patients with
narrow QRS and baseline mechanical asynchrony
significantly improves LVEF, 6MWD and NYHA
compared to their baseline. Further larger rando-
mized trials would be needed before we can draw
definite conclusion about benefit of CRT in heart
failure patients with narrow QRS complex.
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